Maxcyte (MXCT) Payables (2020 - 2026)

Maxcyte (MXCT) has 7 years of Payables data on file, last reported at $1.2 million in Q1 2026.

• Quarterly Payables fell 47.52% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 47.52% YoY) and the FY2025 annual result came in at $1.4 million, up 3.17% from the prior year.
• Payables retreated to $1.2 million in Q1 2026 per MXCT's latest filing, from $1.4 million in the prior quarter.
• Across five years, Payables topped out at $4.4 million in Q1 2022 and bottomed at $292000.0 in Q4 2022.
• The 5-year median for Payables is $1.4 million (2025), against an average of $1.7 million.
• The widest annual swing landed in 2022, when Payables slumped 83.96%; it then jumped 317.6% in 2024.
• Tracing MXCT's Payables over 5 years: stood at $292000.0 in 2022, then jumped by 154.45% to $743000.0 in 2023, then jumped by 82.77% to $1.4 million in 2024, then rose by 3.17% to $1.4 million in 2025, then fell by 14.63% to $1.2 million in 2026.
• Per Business Quant, the three latest MXCT Payables figures stand at $1.2 million (Q1 2026), $1.4 million (Q4 2025), and $1.3 million (Q3 2025).

Peer Comparison